Objective
Research objectives and content
Pohl (Padl human homologue) is a novel and highly conserved component of the human 26S proteosome that confers resistance to some chemotherapic drugs when overexpressed in mammalian cells, as the homologue of fission yeast Padl (V. Spataro et al. J. Biol. Chem.. 272, 30470-30475,1997). We aim to study the significance of Pohl in human tumour cell multi-drug resistance by exploting the NCI panel of 6( tumour cell lines. In order to investigate the mechanism of drug resistance in more detail, expression of Pohl at different levels, by a regulatable expression system, will be carried out in a selected tumour cell line. Furthermore, in order to define the normal physiological role of Pohl I, its expression and activity will be analysed after exposure of the cells to some stresses, such as drug exposure and hypoxia. Crml is a second determinant of multi-drug resistance, conserved from yeast to human: whose function i! involved in nuclear export...Defect in this process could be relevant for tumour progression, since human Crml interacts with the potential oncogenic nucleosporin, encoded by CAN gene. We propose to use yeas genetics in order to identify mutant drugs resistance-inducing alleles of hCRM I, and to perform immunochemical analysis of hCRM I expression.
Training content (objective, benefit and expected impact)
The aim is to achieve a better and comprehensive understanding of the extent and nature of involvement a these new genes in human tumour drug resistance pathways in order to pave the way for a more efffective cancer therapy.
Links with industry / industrial relevance (22)
By discovering new drugs able to block the uncontrolled growth in cancer cells, they could have a potential at commercial level.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences genetics
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance multidrug resistance
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
WC2A 3PX London
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.